/Aflac%20Inc_%20corporate%20building-%20by%20Ken%20Wolter%20via%20Shutterstock.jpg)
Columbus, Georgia-based Aflac Incorporated (AFL) operates as a holding company, offering supplemental health insurance and life insurance through its subsidiaries. With a market cap of $57.2 billion, Aflac sells its products through individual brokers, corporates, corporate agencies, banks, etc., and operates through Aflac Japan and Aflac U.S. segments.
Companies worth $10 billion or more are generally described as "large-cap stocks." Aflac fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the insurance industry.
AFL touched its all-time high of $115.50 on Oct. 4, 2024, and is currently trading 7.4% below that peak. Meanwhile, AFL stock has observed a 4.6% uptick over the past three months, outperforming the S&P 500 Index’s ($SPX) 9.1% surge during the same time frame.
Aflac’s performance has remained grim over the longer term as well. AFL stock has gained a modest 3.4% on a YTD basis and dipped 2.5% over the past 52 weeks, lagging behind SPX’s 10.2% gains in 2025 and 17.8% surge over the past year.
To confirm the downtrend and recent upturn, AFL traded below its 50-day and 200-day moving averages between May to July, before climbing above the moving averages in August.
Aflac’s stock prices gained 3.4% in the trading session following the release of its better-than-expected Q2 results on Aug. 5. During the quarter, Aflac observed a net investment loss of $421 million, compared to $696 million in net investment gains reported in the year-ago quarter. This led to a 19% year-over-year drop in its overall revenues to $4.2 billion. However, this figure surpassed the Street’s expectations by 2.3%.
Meanwhile, the company experienced a notable improvement in non-GAAP margins. Its adjusted EPS dipped by a much more modest 2.7% year-over-year to $1.78 and exceeded consensus estimates by 4.1%.
When compared to its peer, Aflac has outperformed MetLife, Inc.’s (MET) 2.9% dip in 2025, but outperformed MET’s 3.8% gains over the past 52 weeks.
Aflac maintains a consensus “Hold” rating among the 17 analysts covering the stock. As of writing, the stock is trading marginally above its mean price target of $106.86.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
